MedImmune, NGM ally to develop drugs for obesity, diabetes

06/18/2013 | PharmaTimes (U.K.)

AstraZeneca's MedImmune unit and NGM Biopharmaceuticals will collaborate in the discovery and development of the latter's enteroendocrine cell program for the treatment of obesity and type 2 diabetes. The firms intend to develop first-in-class peptide and antibody treatments based on the EEC hormones. The deal entitles NGM to upfront payment, research funding, milestone fees and royalties.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC